Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cerebrospinal Fluid01:21

Cerebrospinal Fluid

3.2K
Cerebrospinal fluid (CSF) is a colorless liquid that flows around the brain and the spinal cord, playing a vital role in the protection, support, and overall function of the central nervous system (CNS). CSF production, circulation, and absorption are tightly regulated processes essential for the brain and spinal cord to function properly.
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain....
3.2K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

709
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
709
Dementia01:30

Dementia

200
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
200

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants.

medRxiv : the preprint server for health sciences·2026
Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026
Same author

Plasma proteomic signatures of cellular aging predict human disease.

Nature medicine·2026
Same author

Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS).

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Acquired vitamin B6 deficiency in POEMS: a marker of disease activity and cause of neuropathy?

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Who I am affects what I do.

Practical neurology·2026
Same journal

Recurrent falls while taking clozapine.

Practical neurology·2026
Same journal

Anti-Ma2 encephalitis: when the examination localises beyond MRI.

Practical neurology·2026
Same journal

Oculopharyngeal muscular dystrophy: diagnosis, management and multisystem care.

Practical neurology·2026
Same journal

Neurological signs of possible diagnostic value in the cognitive clinic: past, present and future.

Practical neurology·2026
Same journal

Longitudinally extensive myelitis in neurosarcoidosis.

Practical neurology·2026
See all related articles

Related Experiment Video

Updated: Sep 30, 2025

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice
06:40

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

Published on: March 19, 2018

63.9K

CSF biomarkers for dementia.

Ashvini Keshavan1, Frankie O'Shea1, Miles D Chapman2,3

  • 1Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

Practical Neurology
|March 18, 2022
PubMed
Summary
This summary is machine-generated.

Cerebrospinal fluid (CSF) biomarker testing aids dementia diagnosis but lacks accessibility. This service shares expertise to improve access for disease-modifying Alzheimer's disease treatments.

Keywords:
CSFalzheimer diseaseamyloiddementiahealth policy & practice

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.9K
Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid
10:23

Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid

Published on: December 4, 2017

9.1K

Related Experiment Videos

Last Updated: Sep 30, 2025

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice
06:40

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

Published on: March 19, 2018

63.9K
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.9K
Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid
10:23

Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid

Published on: December 4, 2017

9.1K

Area of Science:

  • Neurology
  • Clinical Chemistry
  • Biomarker Discovery

Background:

  • Cerebrospinal fluid (CSF) biomarker testing is recommended by some guidelines for dementia diagnosis.
  • Current accessibility of CSF biomarker testing is limited for many patients who could benefit from altered management.
  • There is a need to expand access to these crucial diagnostic tools.

Purpose of the Study:

  • To share experiences from running a clinical cognitive CSF service.
  • To discuss recent advancements in laboratory testing for dementia biomarkers.
  • To advocate for broader access to CSF biomarkers in clinical practice.

Main Methods:

  • Review of clinical cognitive CSF service operations.
  • Discussion of new laboratory testing developments, including CSF amyloid-β 42/40 ratio and automated assays.
  • Emphasis on collaborative work between clinicians and laboratory staff, and preanalytical sample handling.

Main Results:

  • The service highlights the importance of collaboration and proper sample handling for accurate interpretation.
  • New assay platforms and biomarker ratios (e.g., amyloid-β 42/40) show promise for improved diagnostics.
  • Factors influencing result interpretation in clinical contexts were identified.

Conclusions:

  • Broadening access to CSF biomarkers is crucial for timely dementia diagnosis and treatment.
  • Sharing clinical expertise, protocols, and interpretation strategies can facilitate wider adoption.
  • Improved access supports pathways to disease-modifying treatments for Alzheimer's disease and other dementias.